ISSN 1920-4159 | J App Pharm
Journal of Applied PharmacyPharmaceuticsNovember 12, 2026
The US FDA has approved Bayer's asundexian (Sunharbo), the first factor XIa inhibitor, to reduce recurrent stroke risk after a non-cardioembolic ischaemic stroke or high-risk TIA. The decision validates a new anticoagulant class designed to separate antithrombotic benefit from bleeding risk.